Lv3
260 积分 2024-01-20 加入
Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients
3个月前
已关闭
Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
3个月前
已完结
Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro
3个月前
已完结
Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice
3个月前
已完结
Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A
3个月前
已完结
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
3个月前
已完结
Tolerance to Factor VIII in the Era of Non-Factor Therapies: Immunological Perspectives and a Systematic Review of the Literature
3个月前
已完结
Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China
4个月前
已完结
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial
9个月前
已完结
Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors
9个月前
已完结
皖公网安备34019202002308
